Mechanism of Action of the LAT1 Inhibitor Being Developed by Our Company
NEWS
-
- 2026.10.19
-
Envalith Co., Ltd. to Initiate Research Coverage of J-Pharma
-
- 2026.10.15
-
J-Pharma Establishes a Business Operations Department － Strengthening the Organizational Structure to Advance Partnerships and Related Activities for Pipeline Programs －
-
- 2026.10.14
-
J-Pharma Decides on Policy to Expand Part A of the Global Phase III Beacon-BTC Study of Nanvuranlat to Japan and South Korea －Leveraging AMED Support to Reduce Financial Burden While Aiming to Generate Clinical Data and Build a Foundation for Future Development－
